Biomarker, molecular, and technologic advances in Urologic pathology, oncology, and imaging

Carla LaShannon Ellis, Lara R. Harik, Cynthia Cohen, Adeboye O. Osunkoya*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Urologic pathology is evolving rapidly. Emerging trends include the expanded diagnostic utility of biomarkers and molecular testing, as well as adapting to the plethora of technical advances occurring in genitourinary oncology, surgical practice, and imaging. We illustrate those trends by highlighting our approach to the diagnostic workup of a few selected disease entities that pathologists may encounter, including newly recognized subtypes of renal cell carcinoma, pheochromocytoma, and prostate cancer, some of which harbor a distinctive chromosomal translocation, gene loss, or mutation. We illustrate applications of immunohistochemistry for differential diagnosis of needle core renal biopsies, intraductal carcinoma of the prostate, and amyloidosis and cite encouraging results from early studies using targeted gene expression panels to predict recurrence after prostate cancer surgery. At our institution, pathologists are working closely with urologic surgeons and interventional radiologists to explore the use of intraoperative frozen sections for margins and nerve sparing during robotic prostatectomy, to pioneer minimally invasive videoscopic inguinal lymphadenectomy, and to refine image-guided needle core biopsies and cryotherapy of prostate cancer as well as blue-light/fluorescence cystoscopy. This collaborative, multidisciplinary approach enhances clinical management and research, and optimizes the care of patients with urologic disorders.

Original languageEnglish (US)
Pages (from-to)499-516
Number of pages18
JournalArchives of Pathology and Laboratory Medicine
Issue number4
StatePublished - Apr 2017

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Biomarker, molecular, and technologic advances in Urologic pathology, oncology, and imaging'. Together they form a unique fingerprint.

Cite this